Cryoport, Inc. balance sheet
At the end of fiscal 2025, Cryoport, Inc. had total assets of $765m, total liabilities of $262m and shareholders' equity of $503m. It held $250m in cash against $186m of debt: net cash of $64.2m.
Balance sheet
| Fiscal year | 2011Mar 2011 | 2012Mar 2012 | 2013Mar 2013 | 2014Mar 2014 | 2015Mar 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | — | — | — | — | — | 5 | 15 | 37 | 47 | 37 | 139 | 29 | 35 | 34 | 250 | 269 |
| Receivables | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 4 | 7 | 31 | 39 | 44 | 42 | 25 | 33 | 36 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 17 | 28 | 26 | 21 | 23 | 22 |
| Total current assets | 10 | 5 | 1 | 1 | 2 | 6 | 17 | 52 | 103 | 147 | 694 | 604 | 535 | 342 | 476 | 460 |
| Goodwill | — | — | — | — | — | — | — | 0 | 11 | 145 | 147 | 151 | 76 | 21 | 22 | 22 |
| Total assets | 11 | 6 | 2 | 2 | 3 | 8 | 20 | 57 | 136 | 552 | 1,113 | 1,039 | 958 | 703 | 765 | 756 |
| Deferred revenue (current) | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 2 |
| Total current liabilities | 3 | 1 | 2 | 4 | 3 | 2 | 2 | 3 | 5 | 35 | 43 | 41 | 46 | 65 | 219 | 221 |
| Long-term debt | — | 0 | 1 | — | — | — | — | — | 0 | 5 | 1 | 0 | 1 | 1 | 1 | 1 |
| Total debt | 2 | 0 | 1 | — | 1 | 0 | 0 | 15 | 0 | 115 | 404 | 407 | 379 | 198 | 186 | 187 |
| Total liabilities | 5 | 2 | 4 | 4 | 3 | 2 | 2 | 18 | 10 | 170 | 471 | 483 | 469 | 302 | 262 | 266 |
| Shareholders' equity | 6 | 4 | −2 | −2 | −0 | 6 | 18 | 39 | 126 | 383 | 642 | 556 | 489 | 402 | 503 | 491 |
| Net debt (negative = net cash) | — | — | — | — | — | −5 | −15 | −23 | −47 | 78 | 265 | 378 | 344 | 164 | −64 | −82 |
| Shares outstanding | — | — | — | — | 15m | 18m | 26m | 30m | 37m | 40m | 50m | 48m | 49m | 50m | 50m | 51m |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Receivables | 43 | 25 | 28 | 33 | 35 | 33 | 39 | 36 |
| Inventory | 24 | 21 | 23 | 23 | 23 | 23 | 22 | 22 |
| Total current assets | 350 | 342 | 411 | 489 | 485 | 476 | 471 | 460 |
| Goodwill | 54 | 21 | 21 | 19 | 22 | 22 | 22 | 22 |
| Total assets | 702 | 703 | 700 | 774 | 774 | 765 | 764 | 756 |
| Deferred revenue (current) | 1 | 1 | 2 | 2 | 1 | 1 | 2 | 2 |
| Total current liabilities | 61 | 65 | 74 | 30 | 31 | 219 | 225 | 221 |
| Long-term debt | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Total debt | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Total liabilities | 283 | 302 | 301 | 259 | 261 | 262 | 269 | 266 |
| Shareholders' equity | 419 | 402 | 399 | 519 | 513 | 503 | 495 | 491 |
| Shares outstanding | 49m | 50m | 50m | 50m | 50m | 50m | 50m | 51m |
Compare with peers
- Cytek Biosciences, Inc. balance sheet
- Maravai Lifesciences Holdings, Inc. balance sheet
- Grail, Inc. balance sheet
- Pacific Biosciences Of California, Inc. balance sheet
- Quanterix Corp balance sheet
Head to head: CTKB vs CYRXCYRX vs MRVICYRX vs GRALCYRX vs PACB
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies